Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

The rapid evolution of SARS-CoV-2 variants has raised concerns with regard to their potential to escape from vaccine-elicited antibodies and anti-spike protein monoclonal antibodies. We report here on an analysis of sera from recovered patients and vaccinated individuals and on neutralization by Re...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takuya Tada, Belinda M. Dcosta, Marie I. Samanovic, Ramin S. Herati, Amber Cornelius, Hao Zhou, Ada Vaill, Wes Kazmierski, Mark J. Mulligan, Nathaniel R. Landau
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2021
Materias:	Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/cc8f89b646aa4935b60240d6b20c5db4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc8f89b646aa4935b60240d6b20c5db4
record_format	dspace
spelling	oai:doaj.org-article:cc8f89b646aa4935b60240d6b20c5db42021-11-03T21:15:03ZConvalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes2150-751110.1128/mBio.00696-21https://doaj.org/article/cc8f89b646aa4935b60240d6b20c5db42021-06-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.00696-21https://doaj.org/toc/2150-7511 The rapid evolution of SARS-CoV-2 variants has raised concerns with regard to their potential to escape from vaccine-elicited antibodies and anti-spike protein monoclonal antibodies. We report here on an analysis of sera from recovered patients and vaccinated individuals and on neutralization by Regeneron therapeutic monoclonal antibodies.Takuya TadaBelinda M. DcostaMarie I. SamanovicRamin S. HeratiAmber CorneliusHao ZhouAda VaillWes KazmierskiMark J. MulliganNathaniel R. LandauAmerican Society for MicrobiologyarticleMicrobiologyQR1-502ENmBio, Vol 12, Iss 3 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Microbiology QR1-502
spellingShingle	Microbiology QR1-502 Takuya Tada Belinda M. Dcosta Marie I. Samanovic Ramin S. Herati Amber Cornelius Hao Zhou Ada Vaill Wes Kazmierski Mark J. Mulligan Nathaniel R. Landau Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
description	The rapid evolution of SARS-CoV-2 variants has raised concerns with regard to their potential to escape from vaccine-elicited antibodies and anti-spike protein monoclonal antibodies. We report here on an analysis of sera from recovered patients and vaccinated individuals and on neutralization by Regeneron therapeutic monoclonal antibodies.
format	article
author	Takuya Tada Belinda M. Dcosta Marie I. Samanovic Ramin S. Herati Amber Cornelius Hao Zhou Ada Vaill Wes Kazmierski Mark J. Mulligan Nathaniel R. Landau
author_facet	Takuya Tada Belinda M. Dcosta Marie I. Samanovic Ramin S. Herati Amber Cornelius Hao Zhou Ada Vaill Wes Kazmierski Mark J. Mulligan Nathaniel R. Landau
author_sort	Takuya Tada
title	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
title_short	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
title_full	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
title_fullStr	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
title_full_unstemmed	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
title_sort	convalescent-phase sera and vaccine-elicited antibodies largely maintain neutralizing titer against global sars-cov-2 variant spikes
publisher	American Society for Microbiology
publishDate	2021
url	https://doaj.org/article/cc8f89b646aa4935b60240d6b20c5db4
work_keys_str_mv	AT takuyatada convalescentphaseseraandvaccineelicitedantibodieslargelymaintainneutralizingtiteragainstglobalsarscov2variantspikes AT belindamdcosta convalescentphaseseraandvaccineelicitedantibodieslargelymaintainneutralizingtiteragainstglobalsarscov2variantspikes AT marieisamanovic convalescentphaseseraandvaccineelicitedantibodieslargelymaintainneutralizingtiteragainstglobalsarscov2variantspikes AT raminsherati convalescentphaseseraandvaccineelicitedantibodieslargelymaintainneutralizingtiteragainstglobalsarscov2variantspikes AT ambercornelius convalescentphaseseraandvaccineelicitedantibodieslargelymaintainneutralizingtiteragainstglobalsarscov2variantspikes AT haozhou convalescentphaseseraandvaccineelicitedantibodieslargelymaintainneutralizingtiteragainstglobalsarscov2variantspikes AT adavaill convalescentphaseseraandvaccineelicitedantibodieslargelymaintainneutralizingtiteragainstglobalsarscov2variantspikes AT weskazmierski convalescentphaseseraandvaccineelicitedantibodieslargelymaintainneutralizingtiteragainstglobalsarscov2variantspikes AT markjmulligan convalescentphaseseraandvaccineelicitedantibodieslargelymaintainneutralizingtiteragainstglobalsarscov2variantspikes AT nathanielrlandau convalescentphaseseraandvaccineelicitedantibodieslargelymaintainneutralizingtiteragainstglobalsarscov2variantspikes
_version_	1718445423693135872

Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes

Ejemplares similares